Share. Connect. Love.

F*CK Cancer

Follow the epic battle of Darrell’s fight with Brain Cancer. I hope to share my journey, with my Best wit and sarcasm. I want no special favors on family games as I stil[...] read more

Latest journal entry

SurvaxM Vaccine - only FDA approval needed to start treatment!!! ...we’ll be coming back east for treatment...expect visits!

I received good news that i’ll Be able to receive the SurVaxM vaccine!  Here’s a little bit about it:
 
SurVaxM (SVN53-67/M57-KLH) is an investigational immunotherapy being developed to treat a type of brain cancer called glioblastoma. The therapy was initially developed at Roswell Park Cancer Institute in Buffalo, New York.

How SurVaxM works
SurVaxM is a type of immunotherapy called a cancer vaccine, which acts to educate the immune system to identify and target cells producing proteins that are associated with cancer.

The immune system recognizes antigens, substances associated with a disease that are not normally produced by the body. Specific immune cells called antigen presenting cells (APCs) identify and process these antigens. They then activate another type of immune cell called T-cells to recognize and kill the cells producing the antigen.

Around 95 percent of glioblastomas produce a protein called survivin, which is rarely present in the body. SurVaxM consists of a peptide, part of the survivin protein, that can be recognized as an antigen by the immune system. The peptide is attached to a metalloprotein called keyhole limpet hemocyanin (KLH), which can boost the immune response against the peptide.

When SurVaxM is injected into the patient, the immune system stimulates the production of T-cells that target the survivin-producing tumor cells, reducing the tumor size or preventing tumor growth.

SurVaxM is administered in combination with the adjuvant or “helper drug” Leukine (sargramostim), which acts to boost the numbers and activity of immune cells such as APCs.

SurVaxM in clinical trials

The results, published in the scientific journal Cancer Immunology, Immunotherapy, reported that the therapy was well tolerated. The most common adverse events were injection site reactions, fatigue, and muscle pain. Six of the eight evaluable patients had a confirmed immune response to the vaccine.

On average, patients whose cancer recurred appeared to have a longer life expectancy, at 12 to 20 or more months, compared to patients receiving only standard-of-care, which is around seven months. Two of the eight patients were still progression-free at the time of last follow-up.

I hope to be the third patient that reaches progression free status at follow-up.i am also continuing to use Optune and receive my other integrated, and complementary care. 

the only step that remains is getting FDA’s ok for me to take the vaccine. (Approval expected in 1-2 weeks...All other hurdles and genetic matching were successfully completed :) We aim to get started on May 20...so with 8 biweekly injections I should complete treatment by July 1...allowing me a few days rest before my 50th birthday!!!

Shawn and I will need to travel to Buffalo NY to receive the 8 treatments (every other week for 2 months...we plan to take in Niagra Falls, the Bay of Fundy and we would also like very much to catchup with our NJ friends,and colleagues. I’ll provide an update when we set our travel plans. ...I’d also love to enjoy a little music in Asbury Park?  Chris, Angela,Cyndi, Paul, Pia, Eric... anyone game?

Music and the shore would  definitelyspark some joy.

FC and enjoy the ones you love!

with gratitude, 

Darrell

 

 

Stay in the know. Sign up to receive email notifications the moment new Journal entries are posted